Cerebral angiopathy is a broad term for diseases that damage the blood vessels of the brain, but in clinical practice it almost always refers to cerebral amyloid angiopathy (CAA), a condition in which sticky protein fragments called amyloid beta accumulate in the walls of the brain’s arteries and arterioles. Signs of CAA are found in roughly half of all people over age 70 at autopsy, though many never experience obvious symptoms during their lifetime.1PubMed Central. Cerebral Amyloid Angiopathy and Blood-Brain Barrier Dysfunction The condition matters because it is a leading cause of spontaneous brain bleeding in older adults, a contributor to cognitive decline, and a complicating factor in the treatment of Alzheimer’s disease.
What Actually Happens Inside the Blood Vessels
In a healthy brain, amyloid beta is produced as a normal byproduct of a larger protein called amyloid precursor protein. The brain has clearance pathways, including drainage along the walls of blood vessels, that usually flush amyloid beta out before it can do damage. In CAA, those clearance routes fail or slow down, and amyloid beta begins to build up in vessel walls instead.2PubMed Central. Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and Alzheimer’s disease Over time, the deposits weaken vessel walls, make them stiff, and disrupt the barrier between the bloodstream and brain tissue. This allows blood to leak into surrounding brain regions, reduces blood flow, and triggers small infarcts that collectively erode brain function.1PubMed Central. Cerebral Amyloid Angiopathy and Blood-Brain Barrier Dysfunction
Several types of cerebral amyloid angiopathy exist, classified by the specific amyloid protein involved. The overwhelmingly common form in older adults involves amyloid beta (often designated Aβ-type CAA), which is the same peptide implicated in Alzheimer’s disease. This sporadic version is what researchers and clinicians typically mean when they say “CAA.”3PubMed Central. Cerebral amyloid angiopathy: emerging concepts Rare hereditary forms also exist, caused by mutations in specific genes. One well-known example is CADASIL syndrome, a genetic small-vessel disease linked to mutations in the NOTCH3 gene on chromosome 19.4Europe PMC. NOTCH3 and CADASIL syndrome: a genetic and structural overview
Who Gets CAA and Why
Age is the single biggest risk factor. The condition is rare in people under 60 and increases sharply after 70. But genetics play a meaningful role in determining who develops severe disease. The apolipoprotein E (APOE) gene is the most significant genetic contributor, with its variants implicated in more than half of all CAA patients.5PubMed Central. Deciphering the role of APOE in cerebral amyloid angiopathy: from genetic insights to therapeutic horizons
The APOE gene comes in three common versions. The ε4 variant, well known for its role in Alzheimer’s risk, also markedly increases the likelihood of severe CAA. In one large autopsy-confirmed study, about three-quarters of people who carried two copies of the ε4 variant had severe CAA, compared with roughly a third of those carrying the more common ε3/ε3 combination.6JAMA Neurology. Clinical Predictors of Severe Cerebral Amyloid Angiopathy and Influence of APOE Genotype in Persons With Pathologically Verified Alzheimer Disease In contrast, the ε2 variant appears to offer some protection.5PubMed Central. Deciphering the role of APOE in cerebral amyloid angiopathy: from genetic insights to therapeutic horizons These odds don’t mean your fate is sealed by a single gene. Carrying ε4 raises your risk; it does not guarantee severe disease.
How CAA Differs From Alzheimer’s Disease
Because both CAA and Alzheimer’s disease involve amyloid beta, people understandably confuse them. The two conditions overlap frequently: many Alzheimer’s patients have coexisting CAA, and vice versa. But the underlying damage is different. In Alzheimer’s, amyloid beta (predominantly a slightly longer form called Aβ42) clumps into plaques within brain tissue itself, triggering inflammation, tau protein tangles, and ultimately the death of neurons. In CAA, a shorter form (Aβ40) deposits primarily within blood vessel walls, where it causes vascular damage, bleeding, and reduced blood flow rather than the direct neuronal destruction that characterizes Alzheimer’s.7Nature Reviews Neurology. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
When both conditions coexist, their contributions to cognitive decline are additive. CAA worsens the brain’s vascular reserve and increases bleeding risk, while Alzheimer’s drives neuronal and cognitive decline through separate mechanisms. This dual burden can make cognitive symptoms worse than either disease would produce alone.7Nature Reviews Neurology. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Symptoms and Warning Signs
CAA can be silent for years. Many people with amyloid deposits in their vessel walls never develop obvious symptoms, and the condition is only discovered incidentally on brain imaging or at autopsy. When symptoms do appear, they generally fall into two categories: bleeding events and cognitive decline.
The most dramatic presentation is a lobar intracerebral hemorrhage, a bleed in the outer layers of the brain (the cortex or just beneath it). These hemorrhages can cause sudden headache, weakness on one side of the body, confusion, or loss of consciousness, depending on their size and location. In one cohort study, about a fifth of patients who initially had only tiny microbleeds (detected on MRI but causing no symptoms) went on to develop a full lobar hemorrhage during follow-up.8PubMed Central. Incidence of Symptomatic Hemorrhage in Patients With Lobar Microbleeds The characteristic pattern in CAA is that these bleeds happen in the brain’s outer cortical regions rather than in the deep central structures where high-blood-pressure-related bleeds typically occur.9Scientific Reports. Differences in lobar microbleed topography in cerebral amyloid angiopathy and hypertensive arteriopathy
The cognitive effects of CAA follow a distinct pattern. Compared with healthy older adults, CAA patients show striking deficits in executive function (the ability to plan, organize, and shift between tasks) and processing speed, while memory performance tends to be less severely affected. This cognitive profile looks more like what’s seen in vascular cognitive impairment than in Alzheimer’s disease, where memory loss is usually the earliest and most prominent feature.10PubMed. Cerebral Amyloid Angiopathy Is Associated With Executive Dysfunction and Mild Cognitive Impairment The distinction matters clinically, because a patient whose thinking has slowed and whose organizational abilities have declined, but whose memory is relatively intact, may be showing signs of vascular damage rather than classic Alzheimer’s pathology.
Some patients also experience transient focal neurological episodes, sometimes called “amyloid spells.” These can mimic a transient ischemic attack (a “mini-stroke”), producing brief episodes of numbness, tingling, weakness, or visual changes that resolve within minutes to hours. They are thought to result from small bleeds in the cortex that irritate nearby brain tissue.
How CAA Is Diagnosed
A definitive diagnosis of CAA requires examining brain tissue under a microscope, which obviously limits its use in living patients. In practice, clinicians rely on a combination of brain imaging and clinical criteria, most commonly the Boston criteria. The recently updated version 2.0 of these criteria improved diagnostic accuracy substantially. Probable CAA now requires at least two strictly lobar hemorrhagic lesions (which may include full bleeds, microbleeds, or cortical superficial siderosis), or at least one such lesion combined with certain white matter features on MRI.11PubMed. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study In validation studies, the v2.0 criteria achieved sensitivity around 75% and specificity around 95% when compared against autopsy-confirmed diagnoses, a significant improvement over the earlier criteria.12PubMed. Validation of the Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy in Patients Presenting With Intracerebral Hemorrhage
MRI Techniques for Detecting Microbleeds
Standard brain MRI can reveal large hemorrhages, but CAA is often defined by its tiny microbleeds, deposits of old blood products left behind by past small leaks. These show up as dark dots on certain MRI sequences. The traditional technique (T2*-weighted gradient-echo imaging) misses roughly a quarter of CAA patients because it is not sensitive enough to detect very small hemorrhages.13PubMed Central. Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging A newer MRI method called susceptibility-weighted imaging (SWI) is considerably better at picking up these microbleeds and is now considered the preferred technique.14PubMed. Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds If you or a family member is being evaluated for possible CAA, it is worth confirming that SWI sequences were included in the scan protocol.
Emerging Biomarkers
Beyond imaging, researchers are increasingly using spinal fluid tests and PET scans to help characterize CAA. Patients with CAA tend to have distinctively lower levels of amyloid beta fragments (Aβ42, Aβ40, and Aβ38) in their cerebrospinal fluid compared to healthy controls, presumably because amyloid is being trapped in vessel walls rather than draining into the fluid normally.15PubMed Central. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy A meta-analysis confirmed this pattern and found that the levels of Aβ40 and Aβ38 in spinal fluid are particularly useful for distinguishing CAA from Alzheimer’s disease, since Aβ42 drops in both conditions but the other fragments drop more sharply in CAA.16PubMed. Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis
Amyloid PET scans, which light up wherever amyloid is deposited in the brain, can also help. In CAA, amyloid tends to accumulate more prominently in the back of the brain (occipital region), while Alzheimer’s shows a more diffuse, whole-brain pattern. A recent meta-analysis found that comparing the occipital-to-global ratio of amyloid PET uptake reliably distinguished CAA from Alzheimer’s.17PubMed Central. Cerebral amyloid angiopathy and amyloid load distribution detected on amyloid-positron emission tomography: A systematic review and meta-analysis These biomarker tools are not yet routine in every hospital, but they are increasingly available at specialized centers and are likely to become standard in coming years.
Treatment and Management
There is currently no treatment that can remove amyloid from brain blood vessels or halt CAA in its tracks. Management focuses on reducing the risk of hemorrhage, managing cognitive symptoms, and treating complications when they arise. Experimental research into improving amyloid clearance from vessels is underway, with several molecular pathways identified as potential drug targets, but nothing has yet reached clinical use for this purpose.18PubMed Central. The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets
Blood pressure control is the single most impactful intervention available today. A landmark trial (PROGRESS) found that blood-pressure-lowering medication reduced the risk of CAA-related brain hemorrhage by about 77%.19PubMed. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial In a separate study of patients who had already had a brain hemorrhage, inadequate blood pressure control was associated with roughly three and a half times the risk of a recurrent lobar bleed compared to well-controlled blood pressure.20JAMA. Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage These findings are striking because high blood pressure does not cause CAA itself; it simply makes weakened amyloid-laden vessels far more likely to rupture.
The Blood-Thinner Dilemma
One of the most vexing clinical problems in CAA involves patients who also have atrial fibrillation or other conditions that normally call for blood-thinning medication. Anticoagulants reduce the risk of clot-based strokes, but in a person with CAA, they can increase the risk of hemorrhagic ones. There is no clear consensus on how to weigh these competing risks. Current guidance calls for individualized decision-making, with doctors weighing each patient’s specific bleeding history, stroke risk, and CAA severity.21PubMed Central. Management of cerebral amyloid angiopathy and atrial fibrillation: We are still far from precision medicine
Even aspirin, often assumed to be harmless, carries risk in this population. After adjusting for other factors, one study found that aspirin use after a brain hemorrhage in CAA patients was associated with roughly four times the risk of a recurrent bleed.22PubMed Central. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy This doesn’t mean every CAA patient must avoid aspirin forever, but it does mean that the decision should be made deliberately, with the bleeding risk explicitly weighed against whatever cardiovascular benefit aspirin might provide.
When Inflammation Joins the Picture
A subset of CAA patients develops an inflammatory complication sometimes called CAA-related inflammation or amyloid-beta-related angiitis. In this condition, the immune system mounts an attack on the amyloid-laden vessel walls, producing swelling, further vessel damage, and sometimes rapid cognitive decline. Brain biopsy in these cases reveals destructive inflammation of vessel walls, often with a specific immune-cell pattern, along with inflammation in the membranes surrounding the brain.23Brain. Aβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy
Unlike ordinary CAA, the inflammatory variant can respond to immunosuppressive treatment. Initial therapy typically involves steroids combined with cyclophosphamide, followed by longer-term maintenance with medications like azathioprine or mycophenolate mofetil.24PubMed. Treatment of Primary Angiitis of the Central Nervous System Studies suggest that maintenance immunosuppression paired with a gradual steroid taper produces the best long-term outcomes.25PubMed. Treatment and Long-Term Outcomes of Primary Central Nervous System Vasculitis Recognizing this treatable subtype is important because without treatment the inflammation continues to destroy vessels, whereas prompt immunosuppression can stabilize or even partially reverse the damage.
Other Conditions That Affect Brain Blood Vessels
Although CAA dominates the conversation around cerebral angiopathy, the term can technically encompass any disease that damages the brain’s vascular system. A few related conditions are worth knowing about because they enter the differential diagnosis or overlap with CAA symptoms.
Reversible cerebral vasoconstriction syndrome (RCVS) involves sudden, severe spasms of brain arteries that temporarily restrict blood flow. It typically strikes as a “thunderclap” headache, an excruciating headache reaching peak intensity within seconds. RCVS is more common in women and can be triggered by certain medications, pregnancy, or sometimes nothing identifiable at all.26Neurocritical Care. Reversible Cerebral Vasoconstriction Syndrome Unlike CAA, RCVS is usually self-limiting: the arterial spasms resolve within weeks, and most patients recover fully, though strokes can occur during the acute phase.
Hypertensive arteriopathy, the vascular damage caused by chronic high blood pressure, is the other major cause of spontaneous brain bleeding and is often the primary alternative diagnosis when CAA is suspected. The distinction matters because the two conditions produce bleeds in different parts of the brain. Hypertensive bleeds tend to occur in deeper brain structures, while CAA bleeds are lobar and cortical. Imaging can often tell them apart: patients with CAA show microbleeds concentrated in the cortex, whereas hypertensive patients show microbleeds deeper in the brain, in subcortical locations.9Scientific Reports. Differences in lobar microbleed topography in cerebral amyloid angiopathy and hypertensive arteriopathy
Sleep, the Glymphatic System, and CAA
One of the more intriguing research directions involves the relationship between sleep and amyloid clearance. The brain’s waste-disposal system, sometimes called the glymphatic system, is most active during deep sleep. There is growing interest in whether disrupted or insufficient deep sleep contributes to amyloid buildup in vessel walls. Early findings in CAA patients suggest that instability in nightly sleep duration and reductions in deep, restorative sleep are associated with worse memory performance, potentially reflecting impaired overnight amyloid clearance.27Stroke. Abstract TP076: Sleep Alterations and Cognitive Function in Cerebral Amyloid Angiopathy
This research is still preliminary, and nobody can claim that better sleep will prevent or reverse CAA. But it raises the possibility that sleep quality could be a modifiable factor, something patients can actually influence, in a disease that currently offers few treatment levers. For someone living with a CAA diagnosis, prioritizing sleep hygiene and addressing sleep disorders like sleep apnea is a low-risk intervention that aligns with what we know about brain clearance mechanisms, even if the evidence specific to CAA is not yet definitive.